TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process
TC BioPharm (NASDAQ: TCBP) has achieved a significant milestone by successfully registering the trademark 'CryoTC®', a proprietary freeze-thaw process for its lead oncology product, OmnImmune®. This innovative process enhances the product's accessibility and storage, establishing it as an 'off the shelf' cell therapy for potential treatments of acute myeloid leukemia and other cancers. With a strong clinical pipeline, TC BioPharm aims to lead in gamma-delta T cell therapies, combining innate and adaptive immune responses to tackle various cancers and viral infections.
- First gamma delta cell therapy company with a frozen/thawed product in the clinic.
- Trademark registration enhances brand protection and innovation credibility.
- CryoTC® process improves product storage and global shipping capabilities.
- Strong clinical pipeline with ongoing Phase 2b/3 trials for OmnImmune®.
- None.
- 6-month shelf-life milestone achieved
- Successful thaw of highly activated Gamma delta cells
EDINBURGH, Scotland, April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it has successfully registered the UK trademark "CryoTC®", for the Company's proprietary process for freezing and thawing of its lead oncology product, OmnImmune®.
CryoTR® is TC BioPharm's unique process of cryopreservation, which is performed in a controlled rate freezer using an optimized protocol. OmnImmune® is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. OmnImmune® comprises GDT cells sourced from healthy donors, activated and expanded in large numbers before being purified formulated, and cryopreserved for subsequent thawing and infusion into patients.
"Being the first gamma delta cell therapy company with a frozen/thawed product in the clinic is yet another milestone achieved by TCBP," said Bryan Kobel, CEO of TC BioPharm. "This novel freeze-thaw process truly establishes OmnImmune® an 'off the shelf' cell therapy, allowing us to campaign manufacture, ship and store the product around the world for the potential treatment of AML and other blood cancers. Given the multiple development trials and programs we are advancing with OmnImmune®, we are pleased to have this trademark contribute to our brand protection and continue to validate our position at the forefront of innovation in the gamma delta vertical."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
Contact:
Chris Camarra
EVP Communications
c.camarra@tcbiopharm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-receives-cryotc-trademark-for-proprietary-cell-freezing-process-301518447.html
SOURCE TC BioPharm
FAQ
What is TC BioPharm's recent achievement regarding CryoTC®?
How does CryoTC® benefit TC BioPharm's OmnImmune® therapy?
What clinical trials is TC BioPharm currently conducting?
What makes TC BioPharm a leader in gamma-delta T cell therapies?
What are the future prospects for TC BioPharm's therapies?
